Study of DQ1001 for relapsed or refractory multiple myeloma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called DQ1001 for people with multiple myeloma that has come back or stopped responding to other treatments. The goal is to see if it can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have multiple myeloma that came back or didn't respond to at least 3 previous treatments.
- Your cancer cells show a specific marker called BCMA or GPRC5D.
- You have measurable signs of the disease in your blood, urine, or bone marrow.
- You are generally able to care for yourself (ECOG score 0-2).
- Your major organs (like heart, liver, kidneys) are functioning well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new kind of immunotherapy called CAR-T that targets BCMA on myeloma cells. It is for people whose multiple myeloma has come back after or not responded to at least two previous treatments.
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
This trial tests a new drug called SENL103 for people with multiple myeloma that has come back or not responded to several prior treatments. The drug aims to target and kill myeloma cells, potentially helping those who have few other options.
This trial tests a new CAR-T cell therapy called CG-105-12 for people with multiple myeloma that has come back or stopped responding to other treatments. It aims to see if this therapy can help when at least 3 prior treatments have failed.
This trial tests a new drug called QI-019B for people with multiple myeloma whose cancer has come back or stopped responding to other treatments. The goal is to see if it is safe and can help shrink or slow the cancer.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
Hear when a new Multiple Myeloma Progression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.